OTC Markets OTCPK - Delayed Quote USD

Fagron NV (ARSUF)

Compare
20.03
0.00
(0.00%)
At close: January 14 at 3:00:00 PM EST
Loading Chart for ARSUF
DELL
  • Previous Close 0.00
  • Open 20.23
  • Bid 15.95 x 36900
  • Ask 18.65 x 38500
  • Day's Range 20.23 - 20.85
  • 52 Week Range 18.06 - 20.85
  • Volume 1,100
  • Avg. Volume 6
  • Market Cap (intraday) 1.459B
  • Beta (5Y Monthly) 0.26
  • PE Ratio (TTM) 18.21
  • EPS (TTM) 1.10
  • Earnings Date Feb 20, 2025
  • Forward Dividend & Yield 0.32 (1.62%)
  • Ex-Dividend Date May 21, 2024
  • 1y Target Est --

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

www.fagron.com

3,647

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ARSUF

View More

Performance Overview: ARSUF

Trailing total returns as of 1/15/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

ARSUF
0.00%
BEL 20
0.40%

1-Year Return

ARSUF
11.35%
BEL 20
14.25%

3-Year Return

ARSUF
26.19%
BEL 20
0.87%

5-Year Return

ARSUF
3.76%
BEL 20
5.47%

Compare To: ARSUF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ARSUF

View More

Valuation Measures

Annual
As of 1/14/2025
  • Market Cap

    1.25B

  • Enterprise Value

    1.53B

  • Trailing P/E

    18.24

  • Forward P/E

    15.75

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.74

  • Price/Book (mrq)

    3.00

  • Enterprise Value/Revenue

    1.82

  • Enterprise Value/EBITDA

    10.18

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.50%

  • Return on Assets (ttm)

    7.18%

  • Return on Equity (ttm)

    17.09%

  • Revenue (ttm)

    820.76M

  • Net Income Avi to Common (ttm)

    77.94M

  • Diluted EPS (ttm)

    1.10

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    98.26M

  • Total Debt/Equity (mrq)

    78.26%

  • Levered Free Cash Flow (ttm)

    49.45M

Research Analysis: ARSUF

View More

Company Insights: ARSUF

Research Reports: ARSUF

View More

People Also Watch